Patents by Inventor Joshua T. PEARSON

Joshua T. PEARSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10829535
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20180319859
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: February 21, 2018
    Publication date: November 8, 2018
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 9932380
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 3, 2018
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20170137485
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 18, 2017
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 9580486
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20140343252
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 20, 2014
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20140286898
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW